| A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic Impairment (NCT05376839) | AbbVie | 2022-07-06 |
| A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016) (NCT05386589) | Merck Sharp & Dohme LLC | 2022-06-14 |
| A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With Normal Liver Function (NCT05419635) | Bayer | 2022-06-14 |
| Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543 (NCT05467722) | Concert Pharmaceuticals | 2022-06-01 |
| To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function (NCT05404529) | Cerevel Therapeutics, LLC | 2022-04-29 |
| Fruquintinib Hepatic Impairment Study (NCT05216367) | Hutchmed | 2022-03-11 |
| Pharmacokinetics Study of FIA586 in Participants With Mild and Moderate Hepatic Impairment (NCT04993157) | Novartis Pharmaceuticals | 2021-12-10 |
| A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937) (NCT05112952) | Janssen Research & Development, LLC | 2021-11-30 |
| Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants (NCT05026996) | Novartis Pharmaceuticals | 2021-11-23 |
| A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairment (NCT05112419) | AstraZeneca | 2021-11-10 |
| Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function. (NCT05078580) | Novartis Pharmaceuticals | 2021-11-10 |
| A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function (NCT05098054) | Takeda | 2021-10-29 |
| Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease (NCT05045482) | Zydus Therapeutics Inc. | 2021-10-21 |
| A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function (NCT04942964) | Astellas Pharma Global Development, Inc. | 2021-09-13 |
| A Single and Repeat Dose Trial in Participants With Hepatic Impairment (NCT05009680) | Galecto Biotech AB | 2021-09-09 |
| A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod (NCT04819464) | Viatris Innovation GmbH | 2021-08-25 |
| A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants (NCT04960124) | Janssen Research & Development, LLC | 2021-08-05 |
| A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment (NCT04752540) | F2G Biotech GmbH | 2021-07-02 |
| Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment (NCT04791553) | SK Life Science, Inc. | 2021-06-17 |
| A Study to Investigate the Influence of Hepatic Impairment on Elpipodect (MK-8189) Treatment (MK-8189-012) (NCT04676425) | Merck Sharp & Dohme LLC | 2021-03-17 |
| A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib (NCT04772612) | Mirati Therapeutics Inc. | 2021-03-12 |
| Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment (NCT05101265) | PharmaMar | 2021-03-09 |
| Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Liver Function (NCT04694365) | Jiangsu HengRui Medicine Co., Ltd. | 2021-03-01 |
| Surufatinib Hepatic Impairment Study (NCT04755075) | Hutchison Medipharma Limited | 2021-02-12 |
| An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants (NCT04631549) | Jiangsu HengRui Medicine Co., Ltd. | 2021-02-03 |
| Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma (NCT04759846) | Pierre Fabre Medicament | 2021-01-21 |
| STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT (NCT04604496) | Pfizer | 2020-12-30 |
| An Investigational Study of SHR6390 in Participants With Mild to Moderate Liver Impairment and Healthy Participants (NCT04631575) | Jiangsu HengRui Medicine Co., Ltd. | 2020-12-01 |
| Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls. (NCT03813979) | Radboud University Medical Center | 2020-11-15 |
| Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment (NCT04573582) | Celgene | 2020-11-13 |
| To Evaluate the Pharmacokinetics and Safety of Yimitasvir Phosphate Capsules in Subjects With Moderate and Severe Liver Function Impairment and in Healthy Subjects (NCT04552808) | Sunshine Lake Pharma Co., Ltd. | 2020-10-19 |
| A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function (NCT04056468) | Millennium Pharmaceuticals, Inc. | 2020-10-09 |
| Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK (NCT04546789) | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 2020-09-30 |
| A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls (NCT04494269) | HK inno.N Corporation | 2020-09-08 |
| A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function (NCT04482270) | Astellas Pharma Global Development, Inc. | 2020-09-02 |
| A Study of JNJ-53718678 in Participants With Hepatic Impairment (NCT04332523) | Janssen Research & Development, LLC | 2020-08-17 |
| Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment (NCT04305392) | Jiangsu HengRui Medicine Co., Ltd. | 2020-08-04 |
| The Effect of Reduced Liver Function on Selatogrel Pharmacokinetics (NCT04406896) | Viatris Innovation GmbH | 2020-07-22 |
| Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function (NCT04469920) | Zydus Therapeutics Inc. | 2020-07-16 |
| The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics (NCT04252495) | Idorsia Pharmaceuticals Ltd. | 2020-06-26 |
| GT-032 Belapectin Hepatic Impairment (NCT04332432) | Galectin Therapeutics Inc. | 2020-06-16 |
| Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment (NCT04293029) | Jiangsu HengRui Medicine Co., Ltd. | 2020-05-20 |
| Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants (NCT04271488) | Eisai Co., Ltd. | 2020-02-27 |
| Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment (NCT04480827) | Galmed Research and Development, Ltd. | 2020-02-13 |
| A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT (NCT04193436) | Pfizer | 2020-01-21 |
| A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment (NCT04225936) | Bristol-Myers Squibb | 2020-01-16 |
| A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function (NCT04241835) | Epizyme, Inc. | 2020-01-15 |
| A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379 (NCT04208399) | Janssen Sciences Ireland UC | 2020-01-09 |
| A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989 (NCT04208386) | Janssen Sciences Ireland UC | 2020-01-08 |
| A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant (NCT06094725) | Corcept Therapeutics | 2020-01-06 |
| KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment (NCT04166942) | Kadmon, a Sanofi Company | 2019-12-11 |
| Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite (NCT04190654) | Kyowa Kirin, Inc. | 2019-11-26 |
| Study of Single-dose DS-3201b in Participants With Hepatic Impairment (NCT04276662) | Daiichi Sankyo | 2019-11-21 |
| Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Hepatic Impairment (NCT04145596) | Sichuan Haisco Pharmaceutical Group Co., Ltd | 2019-11-14 |
| A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function (NCT04154774) | Janssen Research & Development, LLC | 2019-11-07 |
| Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects (NCT04091061) | Pfizer | 2019-10-03 |
| A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment (NCT03983161) | Celgene | 2019-09-04 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers (NCT04016077) | Pfizer | 2019-07-19 |
| A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function (NCT03902002) | Biogen | 2019-07-19 |
| Study of Nalbuphine ER in Participants With Hepatic Impairment (NCT04020016) | Trevi Therapeutics | 2019-06-12 |
| A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment (NCT03816631) | Janssen-Cilag International NV | 2019-05-28 |
| Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function (NCT03962049) | ObsEva SA | 2019-05-15 |
| Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects (NCT03824678) | Celgene | 2019-02-13 |
| Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients (NCT03765671) | Genfit | 2018-12-12 |
| A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants (NCT05436912) | Eli Lilly and Company | 2018-12-10 |
| A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects (NCT03742882) | Celgene | 2018-12-06 |
| A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib (NCT03587363) | Janssen Research & Development, LLC | 2018-12-06 |
| Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite (NCT03968848) | Acerta Pharma BV | 2018-11-12 |
| Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects (NCT03802786) | Poxel SA | 2018-11-06 |
| A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib (NCT03627754) | Pfizer | 2018-11-05 |
| Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects (NCT04643795) | Madrigal Pharmaceuticals, Inc. | 2018-10-25 |
| A Safety Study of Tucatinib in Healthy and Hepatically-Impaired Subjects (NCT03722823) | Seagen Inc. | 2018-10-10 |
| Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs (NCT03706898) | Viriom | 2018-10-01 |
| Tepotinib Hepatic Impairment Trial (NCT03546608) | EMD Serono Research & Development Institute, Inc. | 2018-06-13 |
| A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function (NCT03799848) | Akebia Therapeutics | 2018-06-12 |
| A Study of LY3314814 in Participants With Liver Impairment (NCT03499041) | Eli Lilly and Company | 2018-06-01 |
| Study of Danicopan in Participants With Hepatic Impairment (NCT03555539) | Alexion Pharmaceuticals, Inc. | 2018-05-01 |
| A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment (NCT03713242) | Idorsia Pharmaceuticals Ltd. | 2018-02-26 |
| Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients (NCT03359850) | Tesaro, Inc. | 2018-02-20 |
| Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects (NCT03440424) | Eisai Inc. | 2018-01-26 |
| Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment (NCT03309202) | Pfizer | 2017-12-19 |
| The Role and Dynamics of Liver Dysfunction in Patients Undergoing Cardiac Surgery (NCT02893657) | Semmelweis University Heart and Vascular Center | 2017-12-01 |
| Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment (NCT03423446) | Lexicon Pharmaceuticals | 2017-11-28 |
| Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects (NCT03369002) | Gilead Sciences | 2017-11-27 |
| The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist (NCT03397888) | Portola Pharmaceuticals | 2017-11-16 |
| A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous TAK-954 (NCT03277274) | Takeda | 2017-11-09 |
| A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment. (NCT03290443) | Celgene | 2017-09-21 |
| A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function (NCT03277755) | Janssen Research & Development, LLC | 2017-09-11 |
| Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant (NCT03212313) | Biotie Therapies Inc. | 2017-06-30 |
| Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites (NCT03376841) | Allergan | 2017-06-06 |
| Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects (NCT03048448) | Novartis Pharmaceuticals | 2017-05-31 |
| Study Investigating the Pharmacokinetic Properties of the Drug Lu AF35700 in Subjects With Liver Impairment and in Healthy Subjects (NCT03189615) | H. Lundbeck A/S | 2017-05-14 |
| Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment (NCT03114540) | Pfizer | 2017-03-17 |
| A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants (NCT02985632) | Bristol-Myers Squibb | 2017-01-11 |
| Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment (NCT02873650) | Novartis Pharmaceuticals | 2016-12-20 |
| Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment (NCT03289234) | Shionogi | 2016-11-16 |
| A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects (NCT02857868) | Novartis Pharmaceuticals | 2016-05-03 |
| Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects (NCT02683577) | Ipsen | 2016-02-01 |
| PK Study of T-817 in Subjects With Hepatic Impairment (NCT02693197) | FUJIFILM Toyama Chemical Co., Ltd. | 2016-02-01 |
| Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment. (NCT02624557) | Novartis Pharmaceuticals | 2015-12-21 |